LGD-4033 Ligandrol

LGD-4033 (Ligandrol) – 10 mg/ml Research Solution: Technical Overview

---

1. Product Advantages

11 Key Differentiators

1. Logistical Excellence
   • Free next-day UK delivery
   • Global shipping with customs-compliant packaging
   • Optional stealth shipping for sensitive research materials
2. Quality Assurance
   • 99% purity (HPLC-verified, batch-specific CoA available)
   • Pharmaceutical-grade synthesis (UK-manufactured)
   • Compounded by SARMs-specialized pharmacologists
3. Research Support
   • 1,000+ peer-reviewed 5-star lab evaluations
   • 24/7 scientific consultation service
   • 90-day satisfaction guarantee

---

2. Compound Profile

Core Specifications

• IUPAC Name: 4-[(2R)-2-[(1R)-2,2,2-Trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile
• Molecular Formula: C14H12F6N2OC14​H12​F6​N2​O
• Concentration: 10 mg/ml (30 ml total volume)
• Carrier Solution: Ethanol/PEG-400 (optimized for in vivo absorption)

---

3. Mechanism of Action

LGD-4033 demonstrates tissue-selective androgen receptor modulation via:

1. Anabolic Signaling: Binds AR in muscle/bone with 10:1 selectivity over prostate tissue
2. Myostatin Inhibition: Reduces myostatin expression by 22–35% in rodent models
3. Glucose Metabolism: Enhances GLUT4 translocation in skeletal muscle (study-linked to NLM trial)

---

4. Research Applications

Experimental Focus Areas

Application	Observed Outcomes
Muscle Hypertrophy	+18% lean mass in 8-week trials (vs placebo)
Osteoporosis Models	14% BMD increase in postmenopausal rodent analogs
Cachexia Studies	31% reduction in muscle wasting markers
Metabolic Syndrome	19% improvement in insulin sensitivity indices

---

5. Quality Protocol

Manufacturing Standards

• Synthesis: ISO 9001-certified UK facility
• Testing: Triple-phase validation (HPLC, MS, NMR)
• Stability: 24-month shelf life under 15–25°C storage

---

6. Experimental Guidelines

Dosing & Administration

• Rodent Models: 0.3–1.0 mg/kg/day (oral/subcutaneous)
• Cycle Duration: 6–10 weeks (optimal anabolic window)
• Stacking: Often paired with $YK-11$ (myostatin inhibitor) for synergistic effects

---

7. Safety Profile

Key Considerations

• HPTA Suppression: Dose-dependent LH reduction (15–30% at 5 mg/day equivalents)
• Lipid Impact: HDL decreases by 20–25% in extended protocols
• Hepatotoxicity: ALT/AST elevation rare (<5% of preclinical cases)

---

8. Regulatory Compliance

• WADA Status: Prohibited in competitive sports (S1.2 category)
• Legal Framework: Schedule IV under UK Misuse of Drugs Regulations 2001
• Ethical Use: Restricted to in vitro/ex vivo research per Declaration of Helsinki

---

9. Comparative Efficacy

Parameter	LGD-4033	Ostarine	Testolone
AR Binding Affinity	1.2 nM	3.8 nM	0.8 nM
Half-Life	36h	24h	60h
Muscle Gain Potential	⭐⭐⭐⭐	⭐⭐⭐	⭐⭐⭐⭐
Clinical Trial Phase	II	II	I

---

10. Future Research Pathways

1. Telomere Dynamics: Androgen-mediated telomerase activation
2. Neuroprotection: AR-mediated CNS plasticity in neurodegenerative models
3. Gender-Specific Responses: Differential effects in XX vs XY chromosomal systems